Drugs / Pembrolizumab/Quavonlimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03179436 | Jul 2017 → Apr 2024 | cancer | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab/Quavonlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03179436 ↗ |
| Modality | Other / unclassified | “Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).” NCT03179436 ↗ |